GlobalData US Prosthetic Heart Valves Market
The report provides market landscape, competitive landscape and market trends information on both market categories – mechanical heart valves and tissue heart valves. The report identifies the key trends shaping and driving market dynamism and provides insight on the emerging players who are expected to challenge the market leaders. The report also analyses the merger and acquisition (M&A) scene with special focus on the most active participants. Finally, the report provides a valuable insight into the pipeline products within the US heart valves market.
US Prosthetic Heart Valves Market To Grow By 4.5% In Forecast Period Driven By New Disruptive Technology And the Trend Towards Early Surgical Intervention
The prosthetic heart valves market in the US is forecast to grow at 4.5% CAGR during 2008-2015 to reach $581.4m by 2015. This growth is expected to be driven by an increasing trend towards early surgical intervention with patients and the launch of transcatheter valves.
Tissue Heart Valves to Drive the Growth of the US Prosthetic Heart Valves Market in 2008–2015
The US tissue heart valves market is forecast to grow at 7.7% CAGR during 2008–2015 to reach $495.3m by 2015. This growth is expected to be driven by continued increasing preference towards tissue heart valves and technological advancements which will improve their durability. Product innovations such as suture less valves which reduce surgery time and improved anti-calcification technology are going to drive the market penetration of pipeline products. This segment contributed 69% to the total prosthetic heart valve market revenues in 2008 and is expected to increase its contribution to 85% by 2015.
Increasing Incidence Of Valvular Heart Disease And Trend Towards Early Surgical Intervention In The US To Drive Procedure Volumes In 2008–2015
Prosthetic heart valve replacement procedures in the US are forecast to grow at 4.5% during 2008-2015 to reach about 118,000 by 2015. This growth is expected to be driven by an aging population leading to a rise in valve disease incidence and improved guidelines on timing for surgical intervention. The incidence of valvular heart disease is expected to increase over the next several decades as the “baby boomer” demographic ages. Valve calcification and degeneration have become the leading causes of aortic stenosis instead of congenital bicuspid disease. The incidence of valve disease in people over the age of 65 is 29% while the incidence in those over 75 is 37%.
In 2006, new guidelines released by ACC/AHA, included more precise and quantitative definitions of mild, moderate and severe valvular disease. This is based on the patient's symptoms and the results of exercise testing, echocardiography and other tests. This change is beginning to encourage early referral of some patients for surgery, even before they develop noticeable symptoms and is expected to drive procedure numbers to some extent.
Technological Advancements For Enhanced Durability and Improved Surgical Procedures To Drive Patient Volumes In 2008–2015
Technological advancements such as: sophisticated anti-calcification technology, improved valve design, and minimal invasive technology, such as transcatheter valve replacement, will enable expansion of the current patient base to include untreated groups. Anti-calcification technologies including treatment with surface active compounds, such as Amino Oleic Acid (AOA) and Diphosphonates, reduce the availability of calcium binding sites and improve valve durability. Other novel designs which improve the hemodynamics of the bioprostheses to better mimic native heart valves are also expected to improve market adoption. Another design innovation, the suture less valve, is claimed to reduce surgery times through less invasive procedures. Other minimally invasive techniques such as transcatheter valves are expected to enable more high risk patients to undergo valve replacement surgery. These products are still undergoing clinical trials, with the earliest expected launch in 2011-2012 for Edwards Lifesciences’
GlobalData: US Prosthetic Heart Valves Market - Tissue Valves To Emerge as the Largest Segment:
http://www.reports-
GlobalData: More market data and market reports:
http://www.reports-
Photo:
http://www.prlog.org/
